Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission
暂无分享,去创建一个
F. Tanser | B. Eley | R. Wood | L. Kuhn | M. Davies | A. Boulle | H. Rabie | S. Sawry | L. Fairlie | J. Giddy | G. Fatti | Karl-Günter Technau | N. Sipambo | P. Nyakato
[1] A. Turkova,et al. Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV , 2019, Therapeutic drug monitoring.
[2] R. Shapiro,et al. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. , 2018, The New England journal of medicine.
[3] T. F. Rinke de Wit,et al. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children , 2017, The Journal of antimicrobial chemotherapy.
[4] M. Cotton,et al. Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis , 2017, Expert opinion on pharmacotherapy.
[5] J. Homberg,et al. Rethinking the risk-benefit ratio of efavirenz in HIV-infected children. , 2016, The Lancet. Infectious diseases.
[6] T. F. Rinke de Wit,et al. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children , 2016, Journal of the International AIDS Society.
[7] T. F. Rinke de Wit,et al. Sequencing paediatric antiretroviral therapy in the context of a public health approach , 2015, Journal of the International AIDS Society.
[8] W. Tsai,et al. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial. , 2015, JAMA.
[9] E. Acosta,et al. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093 , 2015, The Pediatric infectious disease journal.
[10] R. Viani,et al. Use of Integrase Inhibitors in HIV-Infected Children and Adolescents , 2015, Drugs.
[11] N. Ford,et al. Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials , 2015, Journal of acquired immune deficiency syndromes.
[12] J. H. van de Wijgert,et al. Safety and Effectiveness of Combination Antiretroviral Therapy during the First Year of Treatment in HIV-1 Infected Rwandan Children: A Prospective Study , 2014, PloS one.
[13] L. Morris,et al. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis , 2014, AIDS.
[14] E. Lowenthal,et al. Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz , 2014, Pediatric health, medicine and therapeutics.
[15] Kara Wools-Kaloustian,et al. Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. , 2012, International journal of epidemiology.
[16] M. Hughes,et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. , 2012, The New England journal of medicine.
[17] M. Egger,et al. Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africa—The IeDEA Southern Africa Collaboration , 2011, Journal of acquired immune deficiency syndromes.
[18] M. Hughes,et al. Antiretroviral treatment for children with peripartum nevirapine exposure. , 2010, The New England journal of medicine.
[19] T. Puthanakit,et al. Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy , 2009, The Pediatric infectious disease journal.